Dashboard
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 5.66 times
2
Flat results in Dec 24
3
With ROCE of 7.2, it has a Very Expensive valuation with a 5.9 Enterprise value to Capital Employed
Loading Valuation Snapshot...
Stock DNA
Pharmaceuticals & Drugs
INR 2,537 Cr (Small Cap)
76.00
33
0.00%
1.15
15.40%
11.64
Revenue and Profits (1 Year):
Net Sales:
10 Cr
(Quarterly Results - Dec 2024)
Net Profit:
1 Cr
Total Returns (Price + Dividend) 
Company does not have enough history
Risk Adjusted Returns v/s Sensex 
Returns Beta
Beta has not been calculated since enough price history is not available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
0.00%
EBIT to Interest (avg)
3.34
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.24
Sales to Capital Employed (avg)
0.17
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
24.12%
ROCE (avg)
-0.82%
ROE (avg)
15.40%
Valuation key factors
Factor
Value
P/E Ratio
76
Industry P/E
33
Price to Book Value
11.64
EV to EBIT
82.73
EV to EBITDA
62.80
EV to Capital Employed
5.94
EV to Sales
12.18
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
7.18%
ROE (Latest)
15.40%
Tecnicals key factors
Indicator
Weekly
Monthly
MACD
RSI
Bollinger Bands
KST
Dow Theory
No Trend
OBV
No Trend
Shareholding Snapshot : Jul 2024
Shareholding Compare (%holding) 
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 0 Schemes
FIIs
Held by 0 FIIs
Promoter with highest holding
Swapnil Jatin Shah (7.72%)
Highest Public shareholder
Icici Prudential Equity Savings Fund (2.94%)
Individual Investors Holdings
Quarterly Results Snapshot (Standalone) - Dec'24 - QoQ
Dec'24
Dec'23
Change(%)
Net Sales
9.59
8.91
7.63%
Operating Profit (PBDIT) excl Other Income
-2.42
-0.53
-356.60%
Interest
2.70
0.67
302.99%
Exceptional Items
0.00
0.00
Standalone Net Profit
1.07
0.20
435.00%
Operating Profit Margin (Excl OI)
-25.23%
-5.95%
-19.28%
Values in Rs Cr.
Net Sales
Not Applicable: The company has declared_date for only one period
Standalone Net Profit
Not Applicable: The company has declared_date for only one period
Annual Results Snapshot (Standalone) - Mar'24
Mar'24
Mar'23
Change(%)
Net Sales
34.01
12.38
174.72%
Operating Profit (PBDIT) excl Other Income
-0.07
-1.78
96.07%
Interest
2.71
2.14
26.64%
Exceptional Items
0.00
0.00
Standalone Net Profit
0.81
1.20
-32.50%
Operating Profit Margin (Excl OI)
-0.21%
-14.38%
14.17%
Values in Rs Cr.
Net Sales
Not Applicable: The company has declared_date for only one period
Standalone Net Profit
Not Applicable: The company has declared_date for only one period
About Senores Pharmaceuticals Ltd 
Senores Pharmaceuticals Ltd
Small Cap
Pharmaceuticals & Drugs
Senores Pharmaceuticals Limited was originally incorporated as "Senores Pharmaceuticals Private Limited" through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre. Thereafter, the name of the Company was changed to "Senores Pharmaceuticals Limited" upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company.
Company Coordinates 
No Company Details Available